Neurosense Therapeutics is trading 12.2% lower at $6.11 amid broader risk-off conditions.
- No company-specific announcement dated September 28 was found; the latest company release was its September 25 business update.
- Reuters reported that the U.S. rejection of Iran’s proposal pushed oil higher, renewed inflation concerns, and lifted Treasury yields.
- Major U.S. indices were also lower, though less sharply than the stock.